Herpes Zoster Ophthalmicus Market Overview
herpes zoster ophthalmicus market size is expected to grow at a steady CAGR of 2.9% in the forecast period from 2022 to 2032. It is set to be valued at US$ 4.7 Billion in 2022 and US$ 8.2 Billion in 2032. The surging geriatric population across the globe is anticipated to fuel the sales of herpes zoster ophthalmicus drugs in the upcoming years.
Herpes zoster ophthalmicus also known as shingles, is a viral disease that causes unilateral painful skin rash in the fifth cranial nerve that is shared by the ocular adnexa and the eye. It mainly occurs in older adults after the reactivation of Latent Varicella-Zoster Virus (VZV) which is present in the cerebral or sensory spinal ganglia.
It negatively affects the immune system of the host and the incidence of this condition grows with age. Thus, it is commonly found in people over the age of 60 years.
Several cases of this disease showcase a prodromal period of eye pain, fever, headache, and malaise before the eruption of the skin rash. A shingles vaccination is recommended by healthcare institutions for the geriatric population suffering from this condition.
Request Sample of the report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8907
Which are Some Prominent Drivers Spearheading Herpes Zoster Ophthalmicus Market Growth?
The increasing awareness about the usage of varicella vaccine among people is a major factor that is set to drive the demand for herpes zoster ophthalmicus drugs. The rising number of immunization programs conducted by government bodies in various countries free of cost is another factor that is projected to bode well for the market.
The emergence of numerous oral medications, such as anti-inflammatory and antiviral drugs is expected to propel the market. Many pharmaceutical companies are also conducting extensive research and development activities to come up with new medications.
In February 2022, for instance, the New England Journal of Medicine published that Oka/Merck VZV, a novel zoster vaccine is capable of lowering the morbidity from postherpetic neuralgia and herpes zoster in older patients. Spurred by the aforementioned factors, the market is estimated to grow at a steady pace in the future years.
Talk to our Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-8907
What are the Challenges Faced by the Herpes Zoster Ophthalmicus Industry?
Weak imbursement coverage, especially in emerging economies may hamper the sales of herpes zoster ophthalmicus drugs in the assessment period. Start-up companies may not always be able to afford technologically advanced healthcare equipment, which can negatively affect the market. The lack of skilled healthcare professionals to provide vaccines to patients is another factor that may hinder the growth in this market.
Why is North America Emerging as an Opportunistic Herpes Zoster Ophthalmicus Market?
The rising prevalence of cancer among the older population in the U.S. is estimated to boost the North America herpes zoster ophthalmicus market growth in the evaluation period. Individuals suffering from cancer are at a high risk of developing herpes zoster ophthalmicus as radiation and chemotherapy can rapidly decrease immunity.
In addition to that, people who have had chickenpox in the past can develop this disease. According to Boston Children’s Hospital, around 4,000,000 people get chickenpox every year and nearly 95% of American adults have had chickenpox in the past. These numbers are set to surge in future, thereby bolstering the market in North America.
How is Asia Pacific Contributing to Growth of the Herpes Zoster Ophthalmicus Market?
The rising government initiatives to promote healthy lifestyle in emerging economies, such as India and China are anticipated to spur the Asia Pacific herpes zoster ophthalmicus market share. The ongoing development of cutting-edge healthcare facilities equipped with skilled medical professionals is also likely to augur well for the market.
The increasing number of R&D activities conducted by prominent players across Asia Pacific to develop new vaccines and drugs to keep patients healthy is set to fuel the growth. Most of these players are striving to launch new medications to reduce hospitalization of patients, which is projected to positively impact the regional market.
Request Discount on the report @ https://www.futuremarketinsights.com/request-discount/rep-gb-8907
Market Competition
Some of the prominent companies operating in the global herpes zoster ophthalmicus market include SteriMax, Abbott, Apotex Inc., Cipla Limited, Novartis International AG, Fresenius Kabi AG, Foamix Ltd., GlaxoSmithKline plc., Merck & Co., TEVA Pharmaceuticals, Cadila Pharmaceuticals, and Mylan N.V. among others.
The global market is moderately fragmented with the presence of a handful of dominant companies. Majority of these companies are focusing on broadening their businesses in the fast-growing and developed markets. To do so, they are consistently launching innovative drugs to meet the high demand from patients worldwide. A few other key players are engaging in mergers and acquisitions to strengthen their positions in this market.
Report Scope
Growth Rate
CAGR of 2.9% from 2022 to 2032
Base Year for Estimation
2021
Historical Data
2015-2020
Forecast Period
2022-2032
Quantitative Units
Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Route of Administration
Treatment Type
Distribution Channel
Regions Covered
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
Japan - Middle East and Africa
Key Countries Profiled - U.S
- Canada
- Brazil
- Argentina
- Germany
- U.K
- France
- Spain
- Italy
- Nordics
- BENELUX
- Australia & New Zealand
- China
- India
- ASEAN
- GCC
- South Africa
Key Companies Profiled
- SteriMax
- Abbott
- Apotex Inc.
- Cipla Limited
- Novartis International AG
- Fresenius Kabi AG
- Foamix Ltd.
- GlaxoSmithKline plc.
- Merck & Co.
- TEVA Pharmaceuticals
- Cadila Pharmaceuticals
- Mylan N.V.
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs